Active ingredientMidostaurinCat. No. P-M124-001CAS 120685-11-2Family · Pharmaceutical analytical standards
Midostaurin
A multi-kinase inhibitor approved in the United States in 2017 for acute myeloid leukaemia with a FLT3 mutation, combined with chemotherapy and together with a diagnostic test that detects the mutation. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It is derived from staurosporine, an alkaloid produced by the bacterium Streptomyces staurosporeus: its chemical name, 4'-N-benzoylstaurosporine, recalls this origin.
Go to the active ingredient →Active ingredientMidostaurinCat. No. P-M124-001CAS 120685-11-2
Isotopically labelled3-Hydroxy Midostaurin-d5 (Mixture of Diastereomers)Cat. No. P-M124-002
Isotopically labelledMidostaurin Impurity 3-d5Cat. No. P-M124-003
Isotopically labelledMidostaurin Impurity 4-d5Cat. No. P-M124-004
Isotopically labelledMidostaurin-d5Cat. No. P-M124-005
Isotopically labelledO-Desmethyl Midostaurin-d5Cat. No. P-M124-006
Impurity3-Hydroxy Midostaurin (Mixture of Diastereomers)Cat. No. P-M124-007CAS 179237-49-1
ImpurityMidostaurin Impurity 1Cat. No. P-M124-008CAS 945260-14-0
ImpurityMidostaurin Impurity 2Cat. No. P-M124-009CAS 155848-20-7
ImpurityO-Desmethyl MidostaurinCat. No. P-M124-010CAS 740816-86-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.